Home  »  Business   »  Geron Corporation (NASDAQ: GERN) Jumped 3.20%, But...

Geron Corporation (NASDAQ: GERN) Jumped 3.20%, But Don’t Be Too Excited

Geron Corporation (NASDAQ:GERN) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 3.20% to the previous day’s close as strong demand from buyers drove the stock to $1.29.

Actively observing the price movement in the last trading, the stock closed the session at $1.25, falling within a range of $1.24 and $1.36. The value of beta (5-year monthly) was 1.08. Referring to stock’s 52-week performance, its high was $1.76, and the low was $0.99. On the whole, GERN has fluctuated by -3.01% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With the market capitalization of Geron Corporation currently standing at about $471.11 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 09, 2022 – Mar 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.1, which is expected to increase to -$0.09 for fiscal year -$0.4 and then to about -$0.4 by fiscal year 2023.

Analysts have estimated the company’s revenue for the quarter at $110k, with a low estimate of $100k and a high estimate of $120k. According to the average forecast, sales growth in current quarter could jump up 2.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $340k, representing a decrease of -75.60% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 4 upward and no downward review(s) in last seven days. We see that GERN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a Hold.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of GERN currently trading nearly -2.01% and -7.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 47.13, while the 7-day volatility ratio is showing 7.23% which for the 30-day chart, stands at 6.84%. Furthermore, Geron Corporation (GERN)’s beta value is 1.01, and its average true range (ATR) is 0.09.

A comparison of Geron Corporation (GERN) with its peers suggests the former has fared considerably weaker in the market. GERN showed an intraday change of 3.20% in last session, and over the past year, it shrunk by -17.83%%. In comparison, CTI BioPharma Corp. (CTIC) has moved higher at 2.23% on the day and was up 160.70% over the past 12 months. On the other hand, the price of Bio-Techne Corporation (TECH) has risen 0.12% on the day. The stock, however, is off -25.39% from where it was a year ago. Additionally, there is a gain of 0.83% for Incyte Corporation (INCY) in last trading while the stock has seen an overall depriciation of -13.33%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.15%.

Data on historical trading for Geron Corporation (NASDAQ:GERN) indicates that the trading volumes over the past 3 months, they’ve averaged 2.63 million. According to company’s latest data on outstanding shares, there are 332.07 million shares outstanding.

Nearly 0.10% of Geron Corporation’s shares belong to company insiders and institutional investors own 49.40% of the company’s shares. The stock has risen by 5.74% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the GERN stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts